Chinese guidelines on management of hepatic encephalopathy in cirrhosis

Xiao-Yuan Xu, Hui-Guo Ding, Wen-Gang Li, Ji-Dong Jia, Lai Wei, Zhong-Ping Duan, Yu-Lan Liu, En-Qiang Ling-Hu, Hui Zhuang, Chinese Society Of Hepatology, Chinese Medical Association, Xiao-Yuan Xu, Hui-Guo Ding, Wen-Gang Li, Ji-Dong Jia, Lai Wei, Zhong-Ping Duan, Yu-Lan Liu, En-Qiang Ling-Hu, Hui Zhuang, Chinese Society Of Hepatology, Chinese Medical Association

Abstract

The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy in cirrhosis based on the published evidence and the panelists' consensus. The guidelines provided recommendations for the diagnosis and management of hepatic encephalopathy (HE) including minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy, emphasizing the importance on screening MHE in patients with end-stage liver diseases. The guidelines emphasized that early identification and timely treatment are the key to improve the prognosis of HE. The principles of treatment include prompt removal of the cause, recovery of acute neuropsychiatric abnormalities to baseline status, primary prevention, and secondary prevention as soon as possible.

Keywords: Diagnosis; Hepatic encephalopathy; Liver cirrhosis; Therapy.

Conflict of interest statement

Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Figures

Figure 1
Figure 1
Clinical diagnosis and treatment process of hepatic encephalopathy associated with cirrhosis. HE: Hepatic encephalopathy; MHE: Minimal hepatic encephalopathy.

References

    1. Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy a critical current review. Hepatol Int. 2018;12:135–147.
    1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–721.
    1. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, Duseja A, Aggarwal R, Amarapurkar D, Sharma P, Madan K, Shah S, Seth AK, Gupta RK, Koshy A, Rai RR, Dilawari JB, Mishra SP, Acharya SK Indian National Association for Study of the Liver. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010;25:1029–1041.
    1. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642–659.
    1. Chinese Society of Gastroenterology; Chinese Society of Hepatology, Chinese Medical Association. [Consensus on the diagnosis and treatment of hepatic encephalopathy] Zhonghua Gan Zang Bing Za Zhi. 2013;21:641–651.
    1. Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol. 2013;19:4984–4991.
    1. Moriwaki H, Shiraki M, Iwasa J, Terakura Y. Hepatic encephalopathy as a complication of liver cirrhosis: an Asian perspective. J Gastroenterol Hepatol. 2010;25:858–863.
    1. Lin Y, Fan YP. [The neuropsychologic tests and the minimal hepatic encephalopathy investigations in liver cirrhotic patients] Zhonghua Gan Zang Bing Za Zhi. 2011;19:65–66.
    1. Guo JS. Epidemiology, diagnosis and treatment of minimal hepatic encephalopathy. Chin J Hepatol. 2014;22:92–93.
    1. Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR. Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clin Gastroenterol Hepatol. 2017;15:565–574.e4.
    1. Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5:S7–S20.
    1. Lu LG. Hepatic encephalopathy: not so far away from us. Chin J Dig. 2017;37:508–512.
    1. Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5:397–403.
    1. Wijarnpreecha K, Chesdachai S, Thongprayoon C, Jaruvongvanich V, Ungprasert P, Cheungpasitporn W. Association of Helicobacter pylori with the Risk of Hepatic Encephalopathy. Dig Dis Sci. 2017;62:3614–3621.
    1. Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168–G175.
    1. Janve VS, Hernandez CC, Verdier KM, Hu N, Macdonald RL. Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function. Ann Neurol. 2016;79:806–825.
    1. Kobtan AA, El-Kalla FS, Soliman HH, Zakaria SS, Goda MA. Higher Grades and Repeated Recurrence of Hepatic Encephalopathy May Be Related to High Serum Manganese Levels. Biol Trace Elem Res. 2016;169:153–158.
    1. Butterworth RF. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol. 2016;160:94–97.
    1. Pereira K, Carrion AF, Martin P, Vaheesan K, Salsamendi J, Doshi M, Yrizarry JM. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy. Liver Int. 2015;35:2487–2494.
    1. Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134–141.
    1. Blei AT, Córdoba J Practice Parameters Committee of the American College of Gastroenterology. Hepatic Encephalopathy. Am J Gastroenterol. 2001;96:1968–1976.
    1. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33:739–747.
    1. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47:67–73.
    1. Agrawal S, Umapathy S, Dhiman RK. Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol. 2015;5:S42–S48.
    1. Wang AJ, Peng AP, Li BM, Gan N, Pei L, Zheng XL, Hong JB, Xiao HY, Zhong JW, Zhu X. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients. World J Gastroenterol. 2017;23:6321–6329.
    1. Iwasa M, Sugimoto R, Mifuji-Moroka R, Hara N, Yoshikawa K, Tanaka H, Eguchi A, Yamamoto N, Sugimoto K, Kobayashi Y, Hasegawa H, Takei Y. Factors contributing to the development of overt encephalopathy in liver cirrhosis patients. Metab Brain Dis. 2016;31:1151–1156.
    1. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004;19:345–349.
    1. Huang H, Wu T, Mao J, Fang Y, Zhang J, Wu L, Zheng S, Lin B, Pan H. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. OMICS. 2015;19:339–345.
    1. Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282–294.
    1. Jeong JY, Jun DW, Bai D, Kim JY, Sohn JH, Ahn SB, Kim SG, Kim TY, Kim HS, Jeong SW, Cho YK, Song DS, Kim HY, Jung YK, Yoon EL. Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. J Korean Med Sci. 2017;32:1484–1490.
    1. Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016;11:e0146076.
    1. Giménez-Garzó C, Garcés JJ, Urios A, Mangas-Losada A, García-García R, González-López O, Giner-Durán R, Escudero-García D, Serra MA, Soria E, Felipo V, Montoliu C. The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients. PLoS One. 2017;12:e0171211.
    1. Hao L, Hu Y, Hou X. [Age-and, education-corrected number connection test and digit symbol test in diagnosis of minimal hepatic encephalopathy] Zhonghua Gan Zang Bing Za Zhi. 2015;23:533–537.
    1. Wuensch T, Ruether DF, Zöllner C, Mueller T, Jung T, Kaffarnik M, Kassner U, Schott E, Kiefer S, Pratschke J, Stockmann M, Jara M. Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. Eur J Gastroenterol Hepatol. 2017;29:456–463.
    1. Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, Luketic V, Stravitz RT, Fuchs M, Thacker LR, Gilles H, White MB, Unser A, Hovermale J, Gavis E, Noble NA, Wade JB. Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2015;13:1828–1835.e1.
    1. Wang Y, Shi XJ, Abuduheilili X, Fan XT, Ma HL, Feng J, Sun J, A LY, He FP. [Critical flicker frequency for the diagnosis of minimal hepatic encephalopathy] Zhonghua Gan Zang Bing Za Zhi. 2013;21:546–547.
    1. Ma QY, Zhu-Ge ZY. Diagnostic value of critical flicker frequency in minimal hepatic encephalopathy. J Clin Hepatol. 2012;28:559–561.
    1. Kircheis G, Hilger N, Häussinger D. Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. Gastroenterology. 2014;146:961–969.
    1. Ampuero J, Simón M, Montoliú C, Jover R, Serra MÁ, Córdoba J, Romero-Gómez M. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. Gastroenterology. 2015;149:1483–1489.
    1. Campagna F, Montagnese S, Ridola L, Senzolo M, Schiff S, De Rui M, Pasquale C, Nardelli S, Pentassuglio I, Merkel C, Angeli P, Riggio O, Amodio P. The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017;66:198–208.
    1. Urios A, Mangas-Losada A, Gimenez-Garzó C, González-López O, Giner-Durán R, Serra MA, Noe E, Felipo V, Montoliu C. Altered postural control and stability in cirrhotic patients with minimal hepatic encephalopathy correlate with cognitive deficits. Liver Int. 2017;37:1013–1022.
    1. Seo K, Jun DW, Kim JK, Ryu H. Multi-Sensory Integration Impairment in Patients with Minimal Hepatic Encephalopathy. Sci Rep. 2017;7:14947.
    1. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, Ubiali E, Amodio P members of the ISHEN commission on Neurophysiological Investigations. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:789–796.
    1. Shi YB, Seng SJ, Guo M, Zhao HL. Analysis of magnetic resonance and CT imaging findings in hepatic encephalopathy. Chin J Pract Nerv Dis. 2016;19:127–127, 128.
    1. Qi R, Zhang LJ, Zhong J, Zhu T, Zhang Z, Xu C, Zheng G, Lu GM. Grey and white matter abnormalities in minimal hepatic encephalopathy: a study combining voxel-based morphometry and tract-based spatial statistics. Eur Radiol. 2013;23:3370–3378.
    1. Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM, Ranjan P, Pandey CM, Narayana PA. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology. 2006;43:698–706.
    1. Zheng G, Zhang LJ, Zhong J, Wang Z, Qi R, Shi D, Lu GM. Cerebral blood flow measured by arterial-spin labeling MRI: a useful biomarker for characterization of minimal hepatic encephalopathy in patients with cirrhosis. Eur J Radiol. 2013;82:1981–1988.
    1. Chen HJ, Chen QF, Yang ZT, Shi HB. Aberrant topological organization of the functional brain network associated with prior overt hepatic encephalopathy in cirrhotic patients. Brain Imaging Behav. 2019;13:771–780.
    1. Chen HJ, Chen QF, Liu J, Shi HB. Aberrant salience network and its functional coupling with default and executive networks in minimal hepatic encephalopathy: a resting-state fMRI study. Sci Rep. 2016;6:27092.
    1. Jiao Y, Tang T, Wang X, Zhu X, Teng G. [Anterior and posterior default mode networks impairments in minimal hepatic encephalopathy] Zhonghua Yi Xue Za Zhi. 2016;96:334–338.
    1. Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146–152.
    1. Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016;10:509–519.
    1. Hanai T, Shiraki M, Watanabe S, Kochi T, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Res. 2017;47:1359–1367.
    1. NeSmith M, Ahn J, Flamm SL. Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. Gastroenterol Hepatol (N Y) 2016;12:91–100.
    1. Yan M. Selection of the diagnostic and therapeutic methods for minimal hepatic encephalopathy. J Clin Hepatol. 2016;32:1092–1099.
    1. Scalzo SJ, Bowden SC, Ambrose ML, Whelan G, Cook MJ. Wernicke-Korsakoff syndrome not related to alcohol use: a systematic review. J Neurol Neurosurg Psychiatry. 2015;86:1362–1368.
    1. Phan AQ, Pacifici M, Esko JD. Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference. Connect Tissue Res. 2018;59:85–98.
    1. Liu A, Yoo ER, Siddique O, Perumpail RB, Cholankeril G, Ahmed A. Hepatic encephalopathy: what the multidisciplinary team can do. J Multidiscip Healthc. 2017;10:113–119.
    1. Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Ann Hepatol. 2017;16:115–122.
    1. Ding HG, Xu XY, Linghu EQ, Jia JD. Guildlines for prevention and treatment of esophageal variceal bleeding in cirrhotic portal hypertension. J Clin Hepatol. 2016;32:220–222.
    1. Chinese Society of Hepatology; Chinese Medical Association. [Guidelines on the management of ascites and complications in cirrhosis] Zhonghua Gan Zang Bing Za Zhi. 2017;25:664–677.
    1. de Lorenzo-Pinto A, García-Sánchez R, Lorenzo-Salinas A. Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm? Rev Esp Enferm Dig. 2017;109:736–737.
    1. Lauridsen MM, Mikkelsen S, Svensson T, Holm J, Klüver C, Gram J, Vilstrup H, Schaffalitzky de Muckadell OB. The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention-A pilot study. PLoS One. 2017;12:e0185412.
    1. Moratalla A, Ampuero J, Bellot P, Gallego-Durán R, Zapater P, Roger M, Figueruela B, Martínez-Moreno B, González-Navajas JM, Such J, Romero-Gómez M, Francés R. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int. 2017;37:212–223.
    1. Singh J, Sharma BC, Puri V, Sachdeva S, Srivastava S. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. Metab Brain Dis. 2017;32:595–605.
    1. Li LJ, Chen CL, Wu ZW, Chen HG, Fu SZ, Sheng JF. Effects of Lactitol on intestinal flora and plasma endotoxin in patients with chronic viral hepatitis. Chin J Infect Dis. 2005;23:395–397.
    1. Gong JS, Zhang YX, Chen H. Safety and efficacy of rifaximin versus nonabsorbable disaccharides in treatment of hepatic encepha: a meta analysis. Clini Focus. 2015;30:191–195.
    1. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;(5):CD003044.
    1. Bai M, Yang Z, Qi X, Fan D, Han G. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28:783–792.
    1. Pratap Mouli V, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, Joshi YK. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res. 2015;45:880–889.
    1. Saab S, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 2016;36:986–993.
    1. Hu BL, Wang HY, Yang GY. Association of Helicobacter pylori infection with hepatic encephalopathy risk: a systematic review. Clin Res Hepatol Gastroenterol. 2013;37:619–625.
    1. Schulz C, Schütte K, Malfertheiner P. Does H. pylori eradication therapy benefit patients with hepatic encephalopathy?: systematic review. J Clin Gastroenterol. 2014;48:491–499.
    1. Schulz C, Schütte K, Reisener N, Voss J, Malfertheiner P. Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy. J Gastrointestin Liver Dis. 2016;25:191–195.
    1. Sahney A, Sharma BC, Jindal A, Anand L, Arora V, Vijayaraghavan R, Dhamija RM, Kumar G, Bhardwaj A, Sarin SK. A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism. Liver Int. 2019;39:684–693.
    1. Jiang Q, Jiang G, Welty TE, Zheng M. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther. 2010;35:333–341.
    1. Zhou ZW, Zhong XN, Zhou BY, Xiang JF, Wang RH, Yi J. [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels] Zhonghua Gan Zang Bing Za Zhi. 2013;21:385–388.
    1. Khamaysi I, William N, Olga A, Alex I, Vladimir M, Kamal D, Nimer A. Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study. J Hepatol. 2011;54:72–77.
    1. Zhao M, Ye DN. Clinical Observation on Treatment of Hepatic Cirrhosis Complicated with Hepatic Encephalopathy by Integrative Chinese and Western Medicine Therapy. Res Integr Trad Chin West Med. 2017;9:6–8.
    1. Zhou Y, Ma YL. Clinical observation of “Yangyin Huatan Xifeng Decoction” in the treatment of recurrent hepatic encephalopathy. Shanghai J Trad Chin Med. 2016;50:42–44.
    1. Gan DN, Ye YA, Jiang F. Analysis on the Preponderant Efficacy of Traditional Chinese Medicine to Treat Minimal Hepatic Encephalopathy. World Chin Med. 2014;4:504–506, 509.
    1. Yao C, Huang G, Wang M, Xia M, Yao F, Niu D, Zhang Y, Li S, Zhong Y. Chinese herbal medicine formula Jieduhuayu granules improves cognitive and neurophysiological functions in patients with cirrhosis who have minimal hepatic encephalopathy: a randomized controlled trial. Complement Ther Med. 2014;22:977–985.
    1. Ge XJ, Zhao CQ, Xu LM. [Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis] Zhonghua Gan Zang Bing Za Zhi. 2017;25:834–840.
    1. Chi XL, Xiao HM. Traditional Chinese medicine prevention and treatment of liver fibrosis under the new situation of prevention and treatment of viral hepatitis. J Clin Hepatol. 2018;34:694–697.
    1. Lu W, Gao YH, Wang ZZ, Cai YS, Yang YQ, Miao YQ, Pei F, Liu XE, Zhuang H. [Effects of Anluohuaxianwan on transforming growth factor-β1 and related signaling pathways in rats with carbon tetrachloride-induced liver fibrosis] Zhonghua Gan Zang Bing Za Zhi. 2017;25:257–262.
    1. Wu G, He H, Li H, Chen W. [Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis] Zhonghua Gan Zang Bing Za Zhi. 2014;22:604–608.
    1. Vaisman N, Katzman H, Carmiel-Haggai M, Lusthaus M, Niv E. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr. 2010;92:137–140.
    1. Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:CD001939.
    1. Kawaguchi T, Taniguchi E, Sata M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutr Clin Pract. 2013;28:580–588.
    1. Mousa N, Abdel-Razik A, Zaher A, Hamed M, Shiha G, Effat N, Elbaz S, Elhelaly R, Hafez M, El-Wakeel N, Eldars W. The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. Therap Adv Gastroenterol. 2016;9:684–691.
    1. Hanish SI, Stein DM, Scalea JR, Essien EO, Thurman P, Hutson WR, Bartlett ST, Barth RN, Scalea TM. Molecular Adsorbent Recirculating System Effectively Replaces Hepatic Function in Severe Acute Liver Failure. Ann Surg. 2017;266:677–684.
    1. Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, Samuel D. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med. 2013;159:522–531.
    1. Osman MA, Sayed MM, Mansour KA, Saleh SA, Ibrahim WA, Abdelhakam SM, Bahaa M, Yousry WA, Elbaz HS, Mikhail RN, Hassan AM, Elsayed EH, Mahmoud DA. Reversibility of minimal hepatic encephalopathy following liver transplantation in Egyptian cirrhotic patients. World J Hepatol. 2016;8:1279–1286.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner